Clinical management of severe active ulcerative colitis in the TNF-a inhibitors era

Main Article Content

Andrea Calafiore *
Fernando Rizzello
Chiara Praticò
Paolo Gionchetti
Carlo Calabrese
Giuseppina Liguori
Massimo Campieri
(*) Corresponding Author:
Andrea Calafiore | calafiore.a@gmail.com

Abstract

Ulcerative colitis (UC) is a chronic inflammation of the coli mucosa clinically characterized by bloody diarrhea, abdominal pain and other systemic symptoms. The onset, as well as subsequent relapses, may occur with varying degrees of clinical and endoscopic activity and extent of disease. The clinical and endoscopic activity varies from mild to severe, while the extent of disease, without interruption, may involve from the rectum up to the entire colon. The severe form, when not properly and promptly treated, can be life-threatening and may determine various complications requiring urgent surgical treatment. Early recognition of severe forms, their treatment and patient monitoring can reduce morbidity and mortality, and improve surgical outcome. Since the 1950s, systemic corticosteroids have been the first-line treatment in severe active UC. Today, appropriate patient monitoring, and recognition of clinical, radiological and laboratory findings indicative of steroid failure guide the clinician in the use of immunomodulatory drugs or suggest indications for surgery. The aim of our study is to review the more recent data and guidelines that could be useful in clinical practice for the management of severe UC.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Most read articles by the same author(s)